Pablo Mozas

Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers ( <scp> <i>IGHV</i> </scp> mutational status and <scp>FISH</scp> cytogenetics) separates patients with different outcome and simplifies the <scp>CLL‐IPI</scp>

Julio Delgado, Michael Doubek, Tycho Baumann et al. · American Journal of Hematology · 2017 · 93 citations · Full text

Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study

Alfredo Rivas‐Delgado, Ferran Nadeu, Anna Enjuanes et al. · Clinical Cancer Research · 2020 · 91 citations · Full text

Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era

Alfredo Rivas‐Delgado, Laura Magnano, Miriam Moreno‐Velázquez et al. · British Journal of Haematology · 2018 · 79 citations · Full text

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol

Álex Bataller, Ana Garrido, Francesca Guijarro et al. · Blood Advances · 2021 · 54 citations · Full text

Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience

Pablo Mozas, Ferran Nadeu, Alfredo Rivas‐Delgado et al. · Blood Cancer Journal · 2020 · 34 citations · Full text